CERA (continuous erythropoiesis receptor activator): Dose-response, pharmacokinetics, and tolerability in phase I multiple ascending dose studies

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 10-11

  Dougherty, F C ^a   Reigner, Bruno ^a   Jordan, Paul ^a   Pannier, Anne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; ERYTHROCYTE COUNT; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; VOLUNTEER;

EID: 15944406754     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Dougherty FC, Reigner B, Jordan P, Pannier A. CERA (Continuous Erythropoiesis Receptor Activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. Poster presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 6692.